Future work to establish the relationship between CB1 and MAGL bioavailability with Aβ and/or tau PET could provide insights for testing and personalizing the therapeutic engagement of endocannabinoid treatment in AD, and will be used to guide our upcoming human PET imaging studies with these radiopharmaceuticals. Here, MGLL is linked to Alzheimer disease.